Bristol-Myers Squibb Company (BMY) |
|
66.54 0.52 (0.79%)
|
01-17 17:37 |
|
Open: |
66.02 |
Pre. Close: |
66.02 |
|
High:
|
66.86 |
Low:
|
65.54 |
|
Volume:
|
10,793,049 |
Market Cap:
|
150,364M |
|
|
|
|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration agreement with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc.; and a discovery collaboration with Insitro, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
66.942 - 67.191 |
67.191 - 67.39 |
|
Low:
|
64.877 - 65.191 |
65.191 - 65.443 |
|
Close:
|
66.068 - 66.553 |
66.553 - 66.944 |
|
Technical analysis |
as of: 2021-01-15 4:38:16 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 78.09  One year: 91.21 |
| Support: |
Support1: 62.57 Support2: 59.92 |
| Resistance: |
Resistance1: 66.86 Resistance2: 78.09 |
| Pivot: |
62.99 |
| Moving Average: |
MA(5): 65.54 MA(20): 62.75
MA(100): 61.33 MA(250): 60.54  |
| MACD: |
MACD(12,26): Signal(9): 0.48 |
| Stochastic oscillator: |
%K(14,3): 87.38 %D(3): 85.18 |
| RSI: |
RSI(14): 70.99 |
| 52-week: |
High: 68.34 Low: 45.76 Change(%): -1.3 |
| Average Vol(K): |
3-Month: 1058170 10-Days: 1235639 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.BMY has closed below upper band by 2.8%. Bollinger Bands are 64.1% wider than normal. The large width of the bands suggest high volatility as compared to BMY's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 15 Jan 2021
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know - Yahoo Finance
Fri, 15 Jan 2021
Is Bristol-Myers Squibb (BMY) Stock a Buy For 2021? - Yahoo Finance
Fri, 15 Jan 2021
Bristol Myers Provides Long-Term Guidance: Stock Could Be Poised To Breakout - Seeking Alpha
Tue, 12 Jan 2021
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Tue, 12 Jan 2021
Bristol-Myers Squibb Could Finally Make Its Move - RealMoney
Mon, 11 Jan 2021
Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript) - Seeking Alpha
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers General |
| Shares Out. (M) |
2,260 |
| Shares Float (M) |
2,230 |
|
% Held by Insiders
|
0.08 |
|
% Held by Institutions
|
75.79 |
|
Shares Short (K)
|
15,410 |
|
Shares Short P. Month (K)
|
16,140 |
Stock Financials |
|
EPS
|
-0.020 |
|
EPS Est This Year
|
3.000 |
|
EPS Est Next Year
|
3.230 |
|
Book Value (p.s.)
|
22.200 |
|
Profit Margin
|
-0.11 |
|
Operating Margin
|
20.04 |
|
Return on Assets (ttm)
|
5.4 |
|
Return on Equity (ttm)
|
-0.1 |
|
Qtrly Rev. Growth
|
75.5 |
|
Gross Profit (p.s.)
|
8.376 |
|
Sales Per Share
|
17.434 |
|
EBITDA (p.s.)
|
7.442 |
|
Qtrly Earnings Growth
|
38.40 |
|
Operating Cash Flow (M)
|
12,420 |
|
Levered Free Cash Flow (M)
|
14,970 |
Stock Valuations |
|
PE Ratio
|
-3327.00 |
|
PEG Ratio
|
0.82 |
|
Price to Book value
|
3.00 |
|
Price to Sales
|
3.82 |
|
Price to Cash Flow
|
12.11 |
Stock Dividends |
|
Dividend
|
1.800 |
|
Forward Dividend
|
1.960 |
|
Dividend Yield
|
0.03 |
|
Dividend Pay Date
|
2021-01-31 |
|
Ex-Dividend Date
|
2020-12-30 |
|
7 Binary Options
|
|
Your Ad Here
|
|
